1183 related articles for article (PubMed ID: 11280751)
1. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
2. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
3. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression.
Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
Cancer Gene Ther; 2001 Oct; 8(10):719-27. PubMed ID: 11687895
[TBL] [Abstract][Full Text] [Related]
4. Requirements for ICAM-1 immunogene therapy of lymphoma.
Kanwar JR; Berg RW; Yang Y; Kanwar RK; Ching LM; Sun X; Krissansen GW
Cancer Gene Ther; 2003 Jun; 10(6):468-76. PubMed ID: 12768192
[TBL] [Abstract][Full Text] [Related]
5. Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ.
Rafiee M; Kanwar JR; Berg RW; Lehnert K; Lisowska K; Krissansen GW
Cancer Gene Ther; 2001 Dec; 8(12):974-81. PubMed ID: 11781660
[TBL] [Abstract][Full Text] [Related]
6. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
7. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
8. Mouse B7-H3 induces antitumor immunity.
Sun X; Vale M; Leung E; Kanwar JR; Gupta R; Krissansen GW
Gene Ther; 2003 Sep; 10(20):1728-34. PubMed ID: 12939639
[TBL] [Abstract][Full Text] [Related]
9. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy.
Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
Gene Ther; 2001 Apr; 8(8):638-45. PubMed ID: 11320410
[TBL] [Abstract][Full Text] [Related]
10. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
Townsend SE; Su FW; Atherton JM; Allison JP
Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
12. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
13. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
[TBL] [Abstract][Full Text] [Related]
14. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
15. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
16. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
[TBL] [Abstract][Full Text] [Related]
17. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
20. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
